NCT05855941Recruiting
Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)
Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)
Source: ClinicalTrials.gov · Last updated 16 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are: * Does advanced medical imaging predict survival? * Can advanced medical imaging improve radiotherapy target planning? * Are advanced medical imaging results associated with risk markers found in tumor tissue? Participants will * Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. * Be subject to clinical follow-up for five years.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 14 Apr 2023
- Start date
- 23 May 2023
- Primary completion date
- May 2032
- Lead sponsor
- Region Västerbotten
- Diseases
- Endometrial cancer, Cervical cancer, Ovarian cancer
- NCT number
- NCT05855941
What you commit to
- Study type: Observational
- Planned participants: 120
- From 23 May 2023 to the primary completion date, May 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or "cancer abdominis".
Other illness
- Imaging findings suggestive of other primary malignancy.
Other
- MRI incompatible devices or patient unable to undergo MRI.
Who the study is looking for
- Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer.
- Known clinical FIGO stage.
- \>18 years old.
- No other known current or previous malignancy within the last 10 years.
Age in the registry: 18 years to - · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Gynecology and Obstetrics, Umea University Hospital Coordinator of this site? Confirm its status | Umeå | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.